|
|
| |
|
Health Risk Assessment We are pleased to be
able to offer you the benefits of advancements in technology
with our comprehensive range of genetic testing for
many treatable and often preventable conditions. Through
lifestyle and environmental changes, it is possible
to alter the course of your life. Being aware of your
susceptibility of acquiring these conditions enables
you to be active in minimizing any possible risks of
developing such.
Please see our complete range of tests and decide which
one is most suited to your needs. Feel free to call
us if you wish to discuss any issues or queries that
you may have.
How it works
- Click order now, fill in details as
requested and one of our team members will
contact you directly to provide you with all
of the necessary information.
- An appointment will be made for you at your nearest
test centre in order to provide your blood sample.
- Payment can be made at the test centre.
- Your sample will be processed at our affiliate
laboratory and the report will be delivered to you
promptly via email.
- If you have any queries please do not hesitate
to contact us and we will
be glad to assist.
|
|
| |
Genetic testing for Type 2 Diabetes - deCODE
T2™
Eastern Biotech offers non invasive DNA-based reference laboratory
tests for four well-validated genetic risk markers for type
2 diabetes,(including TCF7L2 gene.) This helps identify patients
at increased risk of developing type 2 diabetes and facilitates
both patients and physicians taking early steps to prevent
disease before it starts. Physicians may work more intensively
with higher-risk patients to encourage lifestyle changes and
patients in turn may be more motivated to comply.
Genetic testing for Atrial Fibrillation- deCODE AF™
deCODE AF™ is the first and only genetic test that offers
insight into an individual’s likelihood of having atrial
fibrillation – a common but difficult to detect cause
of ischaemic stroke and myocardial infarction. Even when the
electrocardiogram is negative, deCODE AF™ test helps
to identify at risk patients and those that may benefit from
anticoagulant therapy to prevent such events as strokes and
heart attacks (myocardial infarctions.)
Genetic testing for Breast Cancer- deCODE Breast Cancer™
deCODE Breast Cancer™ is a DNA based test for multiple
risk factors for the common forms of breast cancer. The test
identifies 7 genetic variants associated with a higher likelihood
of developing breast cancer independent of family history.
This offers the Physician the opportunity to begin advanced
screening or initiate early treatment in those who are at
increased risk.
The test multiplies the individual risk markers to create
a genetic profile that defines the relative risk of developing
breast cancer, ranging from 0.4 (no risk variants) to approximately
4 fold (all 7 risk variants), compared with the general population.
Genetic risk defined by the test is independent of conventional
risk factors for breast cancer, including family history,
which are used to determine which higher risk women benefit
from more intensive management to detect or prevent breast
cancer.
Patients with a higher risk may benefit from more intensive
screening with magnetic resonance imaging in addition to routine
mammography as recommended. Women under 60 years of age with
a higher genetic risk may be candidates for preventative treatment
once the risk factor is identified. Some of the markers in
the test modulate the lifetime risk for early breast cancer
in BRCA1 and BRCA2 mutation carriers thus facilitating early
cancer management.
Genetic risk for Prostate Cancer- deCODEProCa™
Eastern Biotech offers the first genetic test to measure multiple
markers of prostate cancer risk, independent of family history.
The test identifies 8 genetic variants that are associated
with increased risk of prostate cancer. Positive results carry
relative risks ranging from 0.33 to over 6-fold compared to
the general population. Two of the markers in particular also
offer additional insight into the aggressiveness of the disease.
Genetic risk for Glaucoma- deCODE Glaucoma™
deCODE Glaucoma™ is a reference laboratory DNA test
for assessing an inherited risk factor for exfoliation glaucoma,
a major subtype of the group of eye disorders termed glaucoma.
Research has shown that two sequence variants in a gene called
LOXL1 significantly increase the risk of developing exfoliation
glaucoma. Independent of the family history for glaucoma,
knowing ones genetic make- up in regard to the risk markers
is relevant, since they may be part of the familial risk or
an addition to it. The deCODE Glaucoma™ test therefore
offers a new factor and added weight to the analysis of an
individual’s risk for glaucoma which may help the individual
and his/her physician to decide on future monitoring, prevention
and/or specific treatments.
Genetic testing for Myocardial Infarction deCODE MI™
deCODE MI™ is a non invasive, DNA based reference laboratory
test to identify patients with an increased risk of myocardial
infarction (heart attack), abdominal aortic aneurysm (AAA)
and intracranial aneurysm.
Myocardial Infarction or ‘heart attack’ is known
to be the leading cause of death for both men and women in
the UAE.
Using pioneering advanced technology, we are pleased to be
able to offer you deCODE MI™ to detect genetic risk
factors for heart attack, helping to provide you with a more
complete picture of individual susceptibility as well as important
information on risk of early-onset disease.
The results of deCODE MI™ are presented as a numerical
score of individual risk of heart attack compared to the population
average.
Patients testing positive have:
A 2-fold increase in the odds of early onset myocardial
infarction for males aged less than 50 and age less than 60
for females.)
A 70% greater risk for both AAA and IA.
The decode MI test may be appropriate for use as part of
an initial comprehensive screening for cardiovascular risk
factors as well as to help determine appropriate monitoring
regimes.
Individuals who test positive may benefit from early intervention
such as more aggressive lipid management.
Using pioneering advanced technology, we are pleased to
be able to offer you deCODE MI™ to detect genetic
risk factors for heart attack, helping to provide you with
a more complete picture of individual susceptibility as
well as important information on risk of early-onset disease.
The results of deCODE MI™ are presented as a numerical
score of individual risk of heart attack compared to the
population average.
|
|
